Quantcast
Home > Quotes > RLM

Realm Therapeutics plc American Depositary Shares (RLM) Quote & Summary Data

RLM 
$2.8
*  
unch
unch
Get RLM Alerts
*Delayed - data as of Jun. 24, 2019  -  Find a broker to begin trading RLM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    RLM Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 2.80 / $ 2.671
Share Volume
22,496
50 Day Avg. Daily Volume
22,825
Previous Close
$ 2.80
52 Week High / Low
$ 13 / $ 1.35
Market Cap
13,054,933
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
22,496
50 Day Avg. Daily Volume:
22,825

Trading Range

The current last sale of $2.80 is 107.41% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.80 $ 13
 Low: $ 2.671 $ 1.35

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on developing novel therapeutics for immune-mediated diseases in adults and children. We are using our proprietary immunomodulatory platform technology -- a high concentration, stabilized formulation of hypochlorous acid, or HOCl -- to develop prescription, topical drugs for the treatment of Atopic Dermatitis, or AD, and other dermatological indications, including Acne Vulgaris, or common Acne, Psoriasis and certain additional indications. Our lead product candidate, PR022, is a non-alcohol based topical gel containing the active ingredient HOCl for the treatment of AD that is in a Phase 2 clinical trial, from which we expect to report top-line data in the third quarter of 2018. Our platform technology, as demonstrated by pre-clinical studies, has the ability to modulate key cytokines that are implicated in multiple dermatological conditions.  ... More ...  

Nasdaq Official Price

Open Price:
$ 2.80
Open Date:
Jun. 24, 2019
Close Price:
$ 2.90
Close Date:
Jun. 24, 2019


Research Brokers before you trade

Want to trade FX?

Analyst Info